Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Trump Slams Drugmakers, Vows to Let U.S. States Buy Cheaper Medicines Abroad

Reuters Staff  |  May 9, 2019

WASHINGTON (Reuters)—U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs on Thursday and vowed to allow U.S. states to buy medicines from other countries if they cost less.

Trump, who campaigned on a platform to reduce drug prices for U.S. consumers, has taken few concrete steps to lower medication costs since taking office in 2017, and has so far largely relied on personal talks with company executives and industry promises to voluntarily roll back prices or limit price hikes.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

At a White House event on hospital billing, the Republican president criticized drug companies for what he said were unfair practices that gave other countries better deals than the United States.

“We may allow states to buy drugs in other countries if we can buy them for … a substantially less price,” Trump said. “The drug companies have treated us very, very unfairly.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Most other developed nations directly or indirectly negotiate drug pricing with companies, and in some cases may deny access to medicines they deem too expensive, while pricing in the United States is left to the free market and set by the drugmakers.

It was not immediately clear how Trump’s administration would move to import medicines from abroad – an idea that has been floated for years but never implemented given U.S. regulations to ensure safety and efficacy and staunch opposition from the industry.

“The rules and regulations within our country have been absolutely atrocious,” Trump said.

“We will allow them, with certain permissions, to go to other countries if they can buy them for 40, 50, 60 percent less,” Trump said. “It’s pretty pathetic but that’s the way it works.”

 

Share: 

Filed under:Drug Updates Tagged with:buying drugs abroadhigh drug pricespharmaceutical industryTrump administration

Related Articles

    Major Drugmakers Push Back in U.S. Price Debate

    January 15, 2016

    SAN FRANCISCO (Reuters)—With a backlash brewing over the price of medicines in the U.S., drugmakers are pushing back with a new message: Most people don’t pay retail. Top executives from Eli Lilly and Co, Merck & Co and Biogen Inc. said in interviews with Reuters this week that the media focus on retail, or “list…

    The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

    June 15, 2017

    Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

    U.S. States Plan Suit to Block Trump Obamacare Subsidies Cut

    October 16, 2017

    WASHINGTON/SAN FRANCISCO (Reuters)—On Friday, California, New York and others states vowed to sue President Donald Trump’s administration to stop him from scrapping a key component of Obamacare, subsidies to insurers that help millions of low-income people pay medical expenses, even as Trump invited Democratic leaders to negotiate a deal. One day after his administration announced…

    Bending, Not Breaking

    August 16, 2019

    “And of course, I am not telling you to do it. That would be illegal.” As a general rule, I try not to instruct my patients to break the law. My business model depends on repeat customers, so placing a patient at risk of getting arrested—even if that risk is remote—doesn’t seem like a good…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences